XOMA Royalty Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Financial Statements Details (Tables)

Consolidated Financial Statements Details (Tables)

12 Months Ended

Dec. 31, 2022

Consolidated Financial Statements Detail

Schedule of cost, accumulated amortization, and net carrying value of intangible assets

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands):


			Accumulated		Net Carrying
	Cost		Amortization		Value
As of December 31, 2022
Ebopiprant IP (Note 4)	$	15,247	$	97	$	15,150
Total intangible assets	$	15,247	$	97	$	15,150

Schedule of projected amortization expense for next five years

The following table presents the projected amortization expense for the next five years (in thousands):


	Intangible Asset
	Amortization

2023	$	897
2024		897
2025		897
2026		897
2027		897
Total	$	4,485

Schedule of accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):


	December 31,		December 31,
	2022		2021
Accrued payroll and benefits		1,449		135
Accrued legal and accounting fees		867		295
Accrued incentive compensation		562		55
Other accrued liabilities		40		40
Total	$	2,918	$	525

Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders

The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):


	Year Ended December 31,
	2022		2021
Numerator
Net (loss) income	$	(17,104)	$	15,798
Less: Series A accumulated dividends		(2,122)		(2,122)
Less: Series B accumulated dividends		(3,350)		(2,438)
Less: Allocation of undistributed earnings to participating securities		—		(3,451)
Net (loss) income (attributable to) available to common stockholders, basic	$	(22,576)	$	7,787
Add: Adjustments to undistributed earnings allocated to participating securities		—		181
Net (loss) income (attributable to) available to common stockholders, diluted	$	(22,576)	$	7,968

Denominator
Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders		11,413		11,288
Effect of dilutive stock options		—		900
Effect of dilutive warrants		—		4
Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders		11,413		12,192
Basic net (loss) income per share (attributable to) available to common stockholders	$	(1.98)	$	0.69
Diluted net (loss) income per share (attributable to) available to common stockholders	$	(1.98)	$	0.65

Schedule of outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):


	Year Ended December 31,
	2022	2021
Convertible preferred stock	5,003	—
Common stock options	885	479
Warrants for common stock	6	—
Total	5,894	479